Neuroscientists find promise in addressing Fragile X afflictions

September 19, 2012

Neuroscientists at New York University have devised a method that has reduced several afflictions associated with Fragile X syndrome (FXS) in laboratory mice. Their findings, which are reported in the journal Neuron, offer new possibilities for addressing FXS, the leading inherited cause of autism and intellectual disability.

Those afflicted with FXS do not possess the protein FMRP, which is a suppressor of . Absent this suppressor, protein synthesis is exaggerated, producing a range of mental and physical disorders.

Previous research has indirectly targeted protein synthesis by seeking to temper, but not block, this process. The NYU researchers, by contrast, sought a more fundamental intervention—removing the enzyme, p70 ribosomal S6 kinase 1, or S6K1, which has previously been shown to regulate protein synthesis in FXS mice. By addressing this phenomenon at the molecular level, they hoped to diminish many of the conditions associated with FXS.

To determine the impact of this intervention, the researchers compared the behaviors of these FXS mice with those normal mice while also observing the of these same FXS mice.

Their results showed that protein synthesis in the FXS mice lacking S6K1 became similar to that of normal mice. Moreover, through a series of experiments and other measurements (e.g., navigating a maze, interacting with other mice), they found both physical and behavioral improvements in the FXS mice:

  • The FXS mice missing the S6K1 enzyme showed greater ability than other FXS mice to adjust their behaviors when facing conditions that were similar, but not identical, to previous experiences. This attribute, , is typically diminished is those afflicted with FXS. In this experiment, the FXS mice missing the S6K1 enzyme were more successful than other FXS mice to navigate a maze that was similar to a maze they had previously mastered.
  • The FXS mice missing the S6K1 enzyme showed enhanced social behaviors, which are measured through a commonly used "social novelty test." Under this method, mice interact with each other multiple times to gauge familiarity. In this experiment, the FXS mice missing the S6K1 enzyme showed greater familiarity with mice they previously encountered than did other FXS mice. Humans afflicted with FXS have diminished abilities for social interaction.
  • The FXS mice missing the S6K1 enzyme showed a correction in three physical traits often associated with this condition: immature dendritic spine morphology, which indicates abnormal connections between neurons, excessive weight gain, and macro-orchidism, or enlarged testicles.
However, the researchers did not find uniform improvements in the tested FXS mice—they still engaged in excessive repetitive behaviors (i.e., repeatedly burying marbles in an experiment), a common trait among those afflicted with FXS.

Nonetheless, the research team said the findings showed remarkable promise.

"We think these results set the stage for a viable pharmacological approach to target S6K1, with the aim of diminishing or even reversing the afflictions associated with ," said Eric Klann, a professor in NYU's Center for Neural Science and the study's senior author.

Explore further: Fragile X syndrome can be reversed in adult mouse brain

Related Stories

Fragile X syndrome can be reversed in adult mouse brain

April 11, 2012
A recent study finds that a new compound reverses many of the major symptoms associated with Fragile X syndrome (FXS), the most common form of inherited intellectual disability and a leading cause of autism. The paper, published ...

Most common form of inherited intellectual disability may be treatable

May 17, 2011
Advancements over the last 10 years in understanding intellectual disability (ID, formerly mental retardation), have led to the once-unimaginable possibility that ID may be treatable, a review of more than 100 studies on ...

Recommended for you

Drug found that induces apoptosis in myofibroblasts reducing fibrosis in scleroderma

December 15, 2017
(Medical Xpress)—An international team of researchers has found that the drug navitoclax can induce apoptosis (self-destruction) in myofibroblasts in mice, reducing the spread of fibrosis in scleroderma. In their paper ...

How defeating THOR could bring a hammer down on cancer

December 14, 2017
It turns out Thor, the Norse god of thunder and the Marvel superhero, has special powers when it comes to cancer too.

Researchers track muscle stem cell dynamics in response to injury and aging

December 14, 2017
A new study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) describes the biology behind why muscle stem cells respond differently to aging or injury. The findings, published in Cell Stem Cell, ...

'Human chronobiome' study informs timing of drug delivery, precision medicine approaches

December 13, 2017
Symptoms and efficacy of medications—and indeed, many aspects of the human body itself—vary by time of day. Physicians tell patients to take their statins at bedtime because the related liver enzymes are more active during ...

Study confirms link between the number of older brothers and increased odds of being homosexual

December 12, 2017
Groundbreaking research led by a team from Brock University has further confirmed that sexual orientation for men is likely determined in the womb.

Potassium is critical to circadian rhythms in human red blood cells

December 12, 2017
An innovative new study from the University of Surrey and Cambridge's MRC Laboratory of Molecular Biology, published in the prestigious journal Nature Communications, has uncovered the secrets of the circadian rhythms in ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.